0
Upcoming Allied Market Research
2023
Pharmaceutical Linctus Market

Pharmaceutical Linctus Market

by Type (Mucolytics, Antitussives, Expectorants), by Vehicle (Tolu Syrup, Invert Syrup, Glycerin, Chloroform, Sorbitol, Water), by Flavoring Agent (Fruit-Flavored Syrup, Lemon Syrup, Blackcurrant Syrup, Others) and by End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A12349
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pharmaceutical Linctus Market

Request Now !

Pharmaceutical linctus is a cough medicine in the form of a syrup. It is taken to often relieve the symptoms of dry cough and sore throat. It is often made in a syrupy medicinal formulation using lemon syrup, fruit-flavored syrup, or tolu syrup. Vehicles that are generally used in the preparation of pharmaceutical linctus include glycerin, sorbitol, or chloroform water. The sticky preparation of linctus containing medicaments exerts local action on the throat's mucous membrane relieving symptoms of pain in the throat. Linctus is a monophasic liquid preparations containing a high concentration of syrup and is advised to be sipped slowly.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.

However, with COVID-19 the supply chain of raw materials required to manufacture pharmaceutical linctus has been disrupted in many countries. In addition, the market growth of pharmaceuticals is declining, as manufacturers of drugs have slowed down their production due to the pandemic. This, in turn, is expected to have a significant impact on the pharmaceutical linctus market.

Top Impacting Factors

The growth of the pharmaceutical linctus market is majorly attributed to increase in the number of cases of respiratory disorders and allergies. Patients with such disorders often suffer from cough, which can be suppressed with the use of linctus.

A higher rate of air pollution across the world is contributing to the growth of the pharmaceutical linctus market. High air pollution in a region often causes symptoms of cough in the population.

In addition, the number of cigarette smokers and people having residence close to heavy traffic lead to increased chances of asthma. These, in turn, is propelling the growth of the pharmaceutical linctus market.

However, pharmaceutical linctus is not recommended in the U.S. or Canada in children who are six years of age or younger. This factor can impede the growth of the pharmaceutical linctus market.

Key Market Trends

Codeine is often used in the preparation of pharmaceutical linctus and was often considered as the gold standard in the preparation of linctus. However, its position is now being questioned as some clinical trials have found it to be ineffective against some forms of coughs.

Asia-Pacific is expected to hold a major share of the pharmaceutical linctus market, owing to rising prevalence of cough in different nations of the region such as India and China. According to the Journal of the Association of Physicians of India, around 54% of the country’s population suffers from cough.

North America is anticipated to dominate the pharmaceutical linctus market, owing to the rising prevalence of cough in the geriatric population and the strong presence of key players of the pharmaceutical linctus market in the region.

Favorable healthcare policies have been launched in many developing nations that are helping make healthcare more accessible to the general public. With this, people will find it easier to afford their treatment regarding respiratory disorders. This, in turn, is expected to boost the market of pharmaceutical linctus during the forecast period.

Key Benefits of the Report

  • This study presents the analytical depiction of the pharmaceutical linctus industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Pharmaceutical Linctus Report

  • Which are the leading players active in the pharmaceutical linctus market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the pharmaceutical linctus in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps in the market?
  • What are the impacts of COVID-19 on the industry?
  • What is pharmaceutical linctus?
  • What are the current and predicted trends of the market?

Pharmaceutical Linctus Market Report Highlights

Aspects Details
By Type
  • Mucolytics
  • Antitussives
  • Expectorants
By Vehicle
  • Tolu Syrup
  • Invert Syrup
  • Glycerin
  • Chloroform
  • Sorbitol
  • Water
By Flavoring Agent
  • Fruit-Flavored Syrup
  • Lemon Syrup
  • Blackcurrant Syrup
  • Others
By End User
  • Hospitals
  • Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Pfizer, Inc., Sanofi, Abbott Laboratories, Johnson and Johnson Services, Inc., Merck KGaA, GlaxoSmithKline PLC, Novartis AG, Reckitt Benckiser Group PLC, Procter and Gamble, Acella Pharmaceuticals, LLC
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: PHARMACEUTICAL LINCTUS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Mucolytics

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Antitussives

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Expectorants

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: PHARMACEUTICAL LINCTUS MARKET, BY VEHICLE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Vehicle

    • 5.2. Tolu Syrup

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Invert Syrup

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Glycerin

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Chloroform

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Sorbitol

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Water

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: PHARMACEUTICAL LINCTUS MARKET, BY FLAVORING AGENT

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Flavoring Agent

    • 6.2. Fruit-Flavored Syrup

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Lemon Syrup

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Blackcurrant Syrup

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: PHARMACEUTICAL LINCTUS MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Hospitals

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Clinics

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Others

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: PHARMACEUTICAL LINCTUS MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Type

      • 8.2.3. Market Size and Forecast, By Vehicle

      • 8.2.4. Market Size and Forecast, By Flavoring Agent

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Pharmaceutical Linctus Market

        • 8.2.7.1. Market Size and Forecast, By Type
        • 8.2.7.2. Market Size and Forecast, By Vehicle
        • 8.2.7.3. Market Size and Forecast, By Flavoring Agent
        • 8.2.7.4. Market Size and Forecast, By End User
      • 8.2.8. Canada Pharmaceutical Linctus Market

        • 8.2.8.1. Market Size and Forecast, By Type
        • 8.2.8.2. Market Size and Forecast, By Vehicle
        • 8.2.8.3. Market Size and Forecast, By Flavoring Agent
        • 8.2.8.4. Market Size and Forecast, By End User
      • 8.2.9. Mexico Pharmaceutical Linctus Market

        • 8.2.9.1. Market Size and Forecast, By Type
        • 8.2.9.2. Market Size and Forecast, By Vehicle
        • 8.2.9.3. Market Size and Forecast, By Flavoring Agent
        • 8.2.9.4. Market Size and Forecast, By End User
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Type

      • 8.3.3. Market Size and Forecast, By Vehicle

      • 8.3.4. Market Size and Forecast, By Flavoring Agent

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Pharmaceutical Linctus Market

        • 8.3.7.1. Market Size and Forecast, By Type
        • 8.3.7.2. Market Size and Forecast, By Vehicle
        • 8.3.7.3. Market Size and Forecast, By Flavoring Agent
        • 8.3.7.4. Market Size and Forecast, By End User
      • 8.3.8. Germany Pharmaceutical Linctus Market

        • 8.3.8.1. Market Size and Forecast, By Type
        • 8.3.8.2. Market Size and Forecast, By Vehicle
        • 8.3.8.3. Market Size and Forecast, By Flavoring Agent
        • 8.3.8.4. Market Size and Forecast, By End User
      • 8.3.9. Italy Pharmaceutical Linctus Market

        • 8.3.9.1. Market Size and Forecast, By Type
        • 8.3.9.2. Market Size and Forecast, By Vehicle
        • 8.3.9.3. Market Size and Forecast, By Flavoring Agent
        • 8.3.9.4. Market Size and Forecast, By End User
      • 8.3.10. Spain Pharmaceutical Linctus Market

        • 8.3.10.1. Market Size and Forecast, By Type
        • 8.3.10.2. Market Size and Forecast, By Vehicle
        • 8.3.10.3. Market Size and Forecast, By Flavoring Agent
        • 8.3.10.4. Market Size and Forecast, By End User
      • 8.3.11. UK Pharmaceutical Linctus Market

        • 8.3.11.1. Market Size and Forecast, By Type
        • 8.3.11.2. Market Size and Forecast, By Vehicle
        • 8.3.11.3. Market Size and Forecast, By Flavoring Agent
        • 8.3.11.4. Market Size and Forecast, By End User
      • 8.3.12. Russia Pharmaceutical Linctus Market

        • 8.3.12.1. Market Size and Forecast, By Type
        • 8.3.12.2. Market Size and Forecast, By Vehicle
        • 8.3.12.3. Market Size and Forecast, By Flavoring Agent
        • 8.3.12.4. Market Size and Forecast, By End User
      • 8.3.13. Rest Of Europe Pharmaceutical Linctus Market

        • 8.3.13.1. Market Size and Forecast, By Type
        • 8.3.13.2. Market Size and Forecast, By Vehicle
        • 8.3.13.3. Market Size and Forecast, By Flavoring Agent
        • 8.3.13.4. Market Size and Forecast, By End User
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Type

      • 8.4.3. Market Size and Forecast, By Vehicle

      • 8.4.4. Market Size and Forecast, By Flavoring Agent

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Pharmaceutical Linctus Market

        • 8.4.7.1. Market Size and Forecast, By Type
        • 8.4.7.2. Market Size and Forecast, By Vehicle
        • 8.4.7.3. Market Size and Forecast, By Flavoring Agent
        • 8.4.7.4. Market Size and Forecast, By End User
      • 8.4.8. Japan Pharmaceutical Linctus Market

        • 8.4.8.1. Market Size and Forecast, By Type
        • 8.4.8.2. Market Size and Forecast, By Vehicle
        • 8.4.8.3. Market Size and Forecast, By Flavoring Agent
        • 8.4.8.4. Market Size and Forecast, By End User
      • 8.4.9. India Pharmaceutical Linctus Market

        • 8.4.9.1. Market Size and Forecast, By Type
        • 8.4.9.2. Market Size and Forecast, By Vehicle
        • 8.4.9.3. Market Size and Forecast, By Flavoring Agent
        • 8.4.9.4. Market Size and Forecast, By End User
      • 8.4.10. South Korea Pharmaceutical Linctus Market

        • 8.4.10.1. Market Size and Forecast, By Type
        • 8.4.10.2. Market Size and Forecast, By Vehicle
        • 8.4.10.3. Market Size and Forecast, By Flavoring Agent
        • 8.4.10.4. Market Size and Forecast, By End User
      • 8.4.11. Australia Pharmaceutical Linctus Market

        • 8.4.11.1. Market Size and Forecast, By Type
        • 8.4.11.2. Market Size and Forecast, By Vehicle
        • 8.4.11.3. Market Size and Forecast, By Flavoring Agent
        • 8.4.11.4. Market Size and Forecast, By End User
      • 8.4.12. Thailand Pharmaceutical Linctus Market

        • 8.4.12.1. Market Size and Forecast, By Type
        • 8.4.12.2. Market Size and Forecast, By Vehicle
        • 8.4.12.3. Market Size and Forecast, By Flavoring Agent
        • 8.4.12.4. Market Size and Forecast, By End User
      • 8.4.13. Malaysia Pharmaceutical Linctus Market

        • 8.4.13.1. Market Size and Forecast, By Type
        • 8.4.13.2. Market Size and Forecast, By Vehicle
        • 8.4.13.3. Market Size and Forecast, By Flavoring Agent
        • 8.4.13.4. Market Size and Forecast, By End User
      • 8.4.14. Indonesia Pharmaceutical Linctus Market

        • 8.4.14.1. Market Size and Forecast, By Type
        • 8.4.14.2. Market Size and Forecast, By Vehicle
        • 8.4.14.3. Market Size and Forecast, By Flavoring Agent
        • 8.4.14.4. Market Size and Forecast, By End User
      • 8.4.15. Rest of Asia Pacific Pharmaceutical Linctus Market

        • 8.4.15.1. Market Size and Forecast, By Type
        • 8.4.15.2. Market Size and Forecast, By Vehicle
        • 8.4.15.3. Market Size and Forecast, By Flavoring Agent
        • 8.4.15.4. Market Size and Forecast, By End User
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Type

      • 8.5.3. Market Size and Forecast, By Vehicle

      • 8.5.4. Market Size and Forecast, By Flavoring Agent

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Pharmaceutical Linctus Market

        • 8.5.7.1. Market Size and Forecast, By Type
        • 8.5.7.2. Market Size and Forecast, By Vehicle
        • 8.5.7.3. Market Size and Forecast, By Flavoring Agent
        • 8.5.7.4. Market Size and Forecast, By End User
      • 8.5.8. South Africa Pharmaceutical Linctus Market

        • 8.5.8.1. Market Size and Forecast, By Type
        • 8.5.8.2. Market Size and Forecast, By Vehicle
        • 8.5.8.3. Market Size and Forecast, By Flavoring Agent
        • 8.5.8.4. Market Size and Forecast, By End User
      • 8.5.9. Saudi Arabia Pharmaceutical Linctus Market

        • 8.5.9.1. Market Size and Forecast, By Type
        • 8.5.9.2. Market Size and Forecast, By Vehicle
        • 8.5.9.3. Market Size and Forecast, By Flavoring Agent
        • 8.5.9.4. Market Size and Forecast, By End User
      • 8.5.10. UAE Pharmaceutical Linctus Market

        • 8.5.10.1. Market Size and Forecast, By Type
        • 8.5.10.2. Market Size and Forecast, By Vehicle
        • 8.5.10.3. Market Size and Forecast, By Flavoring Agent
        • 8.5.10.4. Market Size and Forecast, By End User
      • 8.5.11. Argentina Pharmaceutical Linctus Market

        • 8.5.11.1. Market Size and Forecast, By Type
        • 8.5.11.2. Market Size and Forecast, By Vehicle
        • 8.5.11.3. Market Size and Forecast, By Flavoring Agent
        • 8.5.11.4. Market Size and Forecast, By End User
      • 8.5.12. Rest of LAMEA Pharmaceutical Linctus Market

        • 8.5.12.1. Market Size and Forecast, By Type
        • 8.5.12.2. Market Size and Forecast, By Vehicle
        • 8.5.12.3. Market Size and Forecast, By Flavoring Agent
        • 8.5.12.4. Market Size and Forecast, By End User
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Pfizer, Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Merck KGaA

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Abbott Laboratories

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Novartis AG

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. GlaxoSmithKline PLC

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Sanofi

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Johnson And Johnson Services, Inc.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Acella Pharmaceuticals, LLC

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Reckitt Benckiser Group PLC

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Procter And Gamble

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL LINCTUS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR MUCOLYTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR ANTITUSSIVES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR EXPECTORANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL LINCTUS MARKET, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR TOLU SYRUP, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR INVERT SYRUP, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR GLYCERIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR CHLOROFORM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR SORBITOL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR WATER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL LINCTUS MARKET, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR FRUIT-FLAVORED SYRUP, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR LEMON SYRUP, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR BLACKCURRANT SYRUP, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL LINCTUS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL LINCTUS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL LINCTUS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA PHARMACEUTICAL LINCTUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. U.S. PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 28. U.S. PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 29. U.S. PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 30. U.S. PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. CANADA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 32. CANADA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 33. CANADA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 34. CANADA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE PHARMACEUTICAL LINCTUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 43. EUROPE PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 50. GERMANY PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 51. GERMANY PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ITALY PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. ITALY PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 54. ITALY PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 55. ITALY PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. UK PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 61. UK PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 62. UK PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 63. UK PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. RUSSIA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. RUSSIA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 66. RUSSIA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 67. RUSSIA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. REST OF EUROPE PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 70. REST OF EUROPE PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 71. REST OF EUROPE PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC PHARMACEUTICAL LINCTUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 75. ASIA-PACIFIC PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 76. ASIA-PACIFIC PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. CHINA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 78. CHINA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 79. CHINA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 80. CHINA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 82. JAPAN PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 83. JAPAN PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 84. JAPAN PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 85. INDIA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 86. INDIA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 87. INDIA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 88. INDIA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH KOREA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH KOREA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 94. AUSTRALIA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 95. AUSTRALIA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 96. AUSTRALIA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. THAILAND PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 98. THAILAND PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 99. THAILAND PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 100. THAILAND PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 101. MALAYSIA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 102. MALAYSIA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 103. MALAYSIA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 104. MALAYSIA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. INDONESIA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 106. INDONESIA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 107. INDONESIA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 108. INDONESIA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 112. REST OF ASIA PACIFIC PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA PHARMACEUTICAL LINCTUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 114. LAMEA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 116. LAMEA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 117. LAMEA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 118. BRAZIL PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 119. BRAZIL PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 120. BRAZIL PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 121. BRAZIL PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 122. SOUTH AFRICA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 123. SOUTH AFRICA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 124. SOUTH AFRICA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 125. SOUTH AFRICA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 126. SAUDI ARABIA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 128. SAUDI ARABIA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 129. SAUDI ARABIA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 130. UAE PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 131. UAE PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 132. UAE PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 133. UAE PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 134. ARGENTINA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 135. ARGENTINA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 136. ARGENTINA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 137. ARGENTINA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA PHARMACEUTICAL LINCTUS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA PHARMACEUTICAL LINCTUS, BY VEHICLE, 2022-2032 ($MILLION)
  • TABLE 140. REST OF LAMEA PHARMACEUTICAL LINCTUS, BY FLAVORING AGENT, 2022-2032 ($MILLION)
  • TABLE 141. REST OF LAMEA PHARMACEUTICAL LINCTUS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 142. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 143. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 144. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 145. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 146. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. MERCK KGAA: KEY EXECUTIVES
  • TABLE 148. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 149. MERCK KGAA: OPERATING SEGMENTS
  • TABLE 150. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 151. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 153. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 154. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 155. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 156. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 158. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 159. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 160. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 161. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 163. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 164. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 165. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 166. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. SANOFI: KEY EXECUTIVES
  • TABLE 168. SANOFI: COMPANY SNAPSHOT
  • TABLE 169. SANOFI: OPERATING SEGMENTS
  • TABLE 170. SANOFI: PRODUCT PORTFOLIO
  • TABLE 171. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. JOHNSON AND JOHNSON SERVICES, INC.: KEY EXECUTIVES
  • TABLE 173. JOHNSON AND JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
  • TABLE 174. JOHNSON AND JOHNSON SERVICES, INC.: OPERATING SEGMENTS
  • TABLE 175. JOHNSON AND JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
  • TABLE 176. JOHNSON AND JOHNSON SERVICES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. ACELLA PHARMACEUTICALS, LLC: KEY EXECUTIVES
  • TABLE 178. ACELLA PHARMACEUTICALS, LLC: COMPANY SNAPSHOT
  • TABLE 179. ACELLA PHARMACEUTICALS, LLC: OPERATING SEGMENTS
  • TABLE 180. ACELLA PHARMACEUTICALS, LLC: PRODUCT PORTFOLIO
  • TABLE 181. ACELLA PHARMACEUTICALS, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. RECKITT BENCKISER GROUP PLC: KEY EXECUTIVES
  • TABLE 183. RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT
  • TABLE 184. RECKITT BENCKISER GROUP PLC: OPERATING SEGMENTS
  • TABLE 185. RECKITT BENCKISER GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 186. RECKITT BENCKISER GROUP PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 187. PROCTER AND GAMBLE: KEY EXECUTIVES
  • TABLE 188. PROCTER AND GAMBLE: COMPANY SNAPSHOT
  • TABLE 189. PROCTER AND GAMBLE: OPERATING SEGMENTS
  • TABLE 190. PROCTER AND GAMBLE: PRODUCT PORTFOLIO
  • TABLE 191. PROCTER AND GAMBLE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL LINCTUS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PHARMACEUTICAL LINCTUS MARKET
  • FIGURE 3. SEGMENTATION PHARMACEUTICAL LINCTUS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PHARMACEUTICAL LINCTUS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPHARMACEUTICAL LINCTUS MARKET
  • FIGURE 11. PHARMACEUTICAL LINCTUS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. PHARMACEUTICAL LINCTUS MARKET FOR MUCOLYTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. PHARMACEUTICAL LINCTUS MARKET FOR ANTITUSSIVES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. PHARMACEUTICAL LINCTUS MARKET FOR EXPECTORANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. PHARMACEUTICAL LINCTUS MARKET SEGMENTATION, BY BY VEHICLE
  • FIGURE 16. PHARMACEUTICAL LINCTUS MARKET FOR TOLU SYRUP, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. PHARMACEUTICAL LINCTUS MARKET FOR INVERT SYRUP, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. PHARMACEUTICAL LINCTUS MARKET FOR GLYCERIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. PHARMACEUTICAL LINCTUS MARKET FOR CHLOROFORM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. PHARMACEUTICAL LINCTUS MARKET FOR SORBITOL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. PHARMACEUTICAL LINCTUS MARKET FOR WATER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. PHARMACEUTICAL LINCTUS MARKET SEGMENTATION, BY BY FLAVORING AGENT
  • FIGURE 23. PHARMACEUTICAL LINCTUS MARKET FOR FRUIT-FLAVORED SYRUP, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. PHARMACEUTICAL LINCTUS MARKET FOR LEMON SYRUP, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. PHARMACEUTICAL LINCTUS MARKET FOR BLACKCURRANT SYRUP, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. PHARMACEUTICAL LINCTUS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. PHARMACEUTICAL LINCTUS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 28. PHARMACEUTICAL LINCTUS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. PHARMACEUTICAL LINCTUS MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. PHARMACEUTICAL LINCTUS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 32. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 33. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 34. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 35. COMPETITIVE DASHBOARD
  • FIGURE 36. COMPETITIVE HEATMAP: PHARMACEUTICAL LINCTUS MARKET
  • FIGURE 37. Top player positioning, 2022
  • FIGURE 38. PFIZER, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. PFIZER, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. MERCK KGAA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. MERCK KGAA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. SANOFI: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. SANOFI: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. JOHNSON AND JOHNSON SERVICES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. ACELLA PHARMACEUTICALS, LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. ACELLA PHARMACEUTICALS, LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. ACELLA PHARMACEUTICALS, LLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. RECKITT BENCKISER GROUP PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. RECKITT BENCKISER GROUP PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. RECKITT BENCKISER GROUP PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 65. PROCTER AND GAMBLE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. PROCTER AND GAMBLE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 67. PROCTER AND GAMBLE: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Pharmaceutical Linctus Market

Start reading.
This Report and over 66,782+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers